Literature DB >> 22612004

Thai Registry in Acute Coronary Syndrome (TRACS)--an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year.

Suphot Srimahachota1, Smonporn Boonyaratavej, Rungsrit Kanjanavanit, Piyamitr Sritara, Rungroj Krittayaphong, Rapeephon Kunjara-Na-ayudhya, Pyatat Tatsanavivat.   

Abstract

BACKGROUND: The Thai Registry of Acute Coronary Syndrome (TRACS) registry was conducted five years after the first Thai Acute Coronary Syndrome (ACS) registry.
OBJECTIVE: To describe demographics, management practices, and in-hospital outcomes of current Thai ACS patients and to seek for any significant changes in this registry from the earlier first Thai ACS registry. MATERIAL AND
METHOD: The TRACS is a multi-centers, prospective, nation-wide registration with 39 participating medical centers. Web-based data entry was used and the data were centrally managed and analyzed.
RESULTS: Between October 007 and December 2008, 2,007 patients were enrolled. Fifty-five percent had ST elevation myocardial infarction (STEMI), 33% had non-ST-elevation myocardial infarction (NSTEMI), and 12% had unstable angina (UA). Overall prevalence of diabetes was 50.7%. The STEMI group was younger predominantly male, with less diabetes than NSTEMI. At presentation, lower percent of cardiogenic shock (7.9%) and cardiac arrest (2.8%) were noted. Sixty seven percent of the STEMI received reperfusion therapy. Thrombolysis was given in 42.6% and primary percutaneous coronary intervention (PCI) was performed in 24.7% of all STEMl patients. Median door-to-needle and door-to-balloon time were 65 and 127 minutes. The median time-to-treatment was 285 min in the thrombolysis group and 324 min in the primary PCI group. Regarding NSTE-ACS, coronary angiography was performed in 38.4% and about one-fourth received revascularization either by PCI or bypass surgery during index admission. In-hospital mortality was 5.3% for STEMI, 5.1% for NSTEMI, and 1.7% for UA. When following the patients up to 12 months, the mortality was 14.1%, 25.0%, and 13.8% respectively.
CONCLUSION: The TRACS registry showed differences in demographic, management practices and in-hospital outcomes of the Thai ACS patients. Although mortality rate in this registry decreased significantly as compared to the first Thai ACS registry, the results had to be interpreted with caution because of the difference in characteristics and severity of the enrolled patients. At 12-month follow-up, the mortality rate was significantly higher in NSTEMI than STEMI or UA patients. Practice management should be considered particularly for the invasive strategy for these groups of patients.

Entities:  

Mesh:

Year:  2012        PMID: 22612004

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  14 in total

1.  Target organ damage and control of cardiovascular risk factors in hypertensive patients. Evidence from the multicenter ESTher registry.

Authors:  R K Reibis; M Huber; M Karoff; W Kamke; R Kreutz; K Wegscheider; H Völler
Journal:  Herz       Date:  2015-01-30       Impact factor: 1.443

2.  Global perspective on acute coronary syndrome: a burden on the young and poor.

Authors:  Rajesh Vedanthan; Benjamin Seligman; Valentin Fuster
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

3.  Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study.

Authors:  Arintaya Phrommintikul; Rungroj Krittayaphong; Wanwarang Wongcharoen; Sukit Yamwong; Smonporn Boonyaratavej; Rapeephon Kunjara-Na-Ayudhya; Pyatat Tatsanavivat; Piyamitr Sritara
Journal:  Singapore Med J       Date:  2017-05-25       Impact factor: 1.858

4.  Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.

Authors:  Khachen Kongpakwattana; Zanfina Ademi; Thanaputt Chaiyasothi; Surakit Nathisuwan; Ella Zomer; Danny Liew; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

5.  Prevalence and predictors associated with in-hospital mortality in acute ST segment elevation myocardial infarction after reperfusion therapy in developing country.

Authors:  Chorchana Wichian; Thotsaporn Morasert; Thanapon Nilmoje; Ply Chichareon
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

6.  Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand.

Authors:  Krittimeth Trerayapiwat; Peerawat Jinatongthai; Prin Vathesatogkit; Piyamitr Sritara; Ninutcha Paengsai; Piyameth Dilokthornsakul; Surakit Nathisuwan; Lan My Le; Nathorn Chaiyakunapruk
Journal:  Lancet Reg Health West Pac       Date:  2022-06-24

7.  Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand.

Authors:  Sukit Yamwong; Unchalee Permsuwan; Sirana Tinmanee; Piyamitr Sritara
Journal:  Health Econ Rev       Date:  2014-11-14

8.  Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study.

Authors:  Dujrudee Chinwong; Jayanton Patumanond; Surarong Chinwong; Khanchai Siriwattana; Siriluck Gunaparn; John Joseph Hall; Arintaya Phrommintikul
Journal:  BMC Cardiovasc Disord       Date:  2015-06-16       Impact factor: 2.298

9.  The prognostic utility of GRACE risk score in predictive cardiovascular event rate in STEMI patients with successful fibrinolysis and delay intervention in non PCI-capable hospital: a retrospective cohort study.

Authors:  Yotsawee Chotechuang; Arintaya Phrommintikul; Roungtiva Muenpa; Jayanton Patumanond; Tuanchai Chaichuen; Srun Kuanprasert; Noparat Thanachikun; Thanawat Benjanuwatra; Apichard Sukonthasarn
Journal:  BMC Cardiovasc Disord       Date:  2016-11-08       Impact factor: 2.298

10.  Association of statin therapy with ventricular arrhythmias among patients with acute coronary syndrome.

Authors:  Sirin Apiyasawat; Piyamitr Sritara; Tachapong Ngarmukos; Charn Sriratanasathavorn; Piya Kasemsuwan
Journal:  Heart Asia       Date:  2013-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.